Испания - испански - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

takeda pharmaceuticals international ag ireland branch - lantano - polvo oral - 1.000 mg - lantano 1000 mg - lantano, carbonato de

Испания - испански - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

takeda pharmaceuticals international ag ireland branch - lantano carbonato - comprimido masticable - 500 mg - lantano carbonato 500 mg - lantano, carbonato de

Испания - испански - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

takeda pharmaceuticals international ag ireland branch - lantano carbonato - comprimido masticable - 750 mg - lantano carbonato 750 mg - lantano, carbonato de

Испания - испански - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

takeda pharmaceuticals international ag ireland branch - lantano - polvo oral - 750 mg - lantano 750 mg - lantano, carbonato de

Испания - испански - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

takeda pharmaceuticals international ag ireland branch - lantano carbonato - comprimido masticable - 1.000 mg - lantano carbonato 1000 mg - lantano, carbonato de

Европейски съюз - испански - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - clorhidrato de guanfacina - trastorno por déficit de atención con hiperactividad - antiadrenergic agents, centrally acting, antihypertensives, - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. intuniv debe ser utilizado como parte de un plan integral de tratamiento para el tdah programa, normalmente incluidas las psicológicas, educativas y sociales de las medidas de.

Европейски съюз - испански - EMA (European Medicines Agency)

takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - agentes antineoplásicos - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.

Европейски съюз - испански - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - carcinoma, pulmón no microcítico - agentes antineoplásicos - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Европейски съюз - испански - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - hormona paratiroidea - hipoparatiroidismo - homeostasis del calcio - natpar está indicado como tratamiento adyuvante de pacientes adultos con hipoparatiroidismo crónico que no pueden controlarse adecuadamente con terapia estándar sola.

Европейски съюз - испански - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - lanadelumab - angioedemas, hereditario - other hematological agents - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in patients aged 2 years and older.